MX2017000582A - Marcadores geneticos para predecir la reactividad a terapia con agente que eleva la lipoproteina de alta densidad (hdl) o que imita la lipoproteina de alta densidad (hdl). - Google Patents
Marcadores geneticos para predecir la reactividad a terapia con agente que eleva la lipoproteina de alta densidad (hdl) o que imita la lipoproteina de alta densidad (hdl).Info
- Publication number
- MX2017000582A MX2017000582A MX2017000582A MX2017000582A MX2017000582A MX 2017000582 A MX2017000582 A MX 2017000582A MX 2017000582 A MX2017000582 A MX 2017000582A MX 2017000582 A MX2017000582 A MX 2017000582A MX 2017000582 A MX2017000582 A MX 2017000582A
- Authority
- MX
- Mexico
- Prior art keywords
- hdl
- raising
- therapy
- genetic markers
- mimicking agent
- Prior art date
Links
- 230000002068 genetic effect Effects 0.000 title 1
- 230000004043 responsiveness Effects 0.000 title 1
- 238000002560 therapeutic procedure Methods 0.000 title 1
- 208000024172 Cardiovascular disease Diseases 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 239000003354 cholesterol ester transfer protein inhibitor Substances 0.000 abstract 1
- 229940125881 cholesteryl ester transfer protein inhibitor Drugs 0.000 abstract 1
- 238000003205 genotyping method Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6806—Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/118—Prognosis of disease development
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
Abstract
La presente invención se refiere a métodos y composiciones de genotipado para seleccionar pacientes con enfermedad cardiovascular quienes se beneficiarán del tratamiento con un agente que eleva la HDL o imita la HDL, en particular con un inhibidor/modulador de la CETP.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP14179048 | 2014-07-30 | ||
PCT/EP2015/067098 WO2016016157A1 (en) | 2014-07-30 | 2015-07-27 | Genetic markers for predicting responsiveness to therapy with hdl-raising or hdl mimicking agent |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2017000582A true MX2017000582A (es) | 2017-04-27 |
Family
ID=51265507
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2017000582A MX2017000582A (es) | 2014-07-30 | 2015-07-27 | Marcadores geneticos para predecir la reactividad a terapia con agente que eleva la lipoproteina de alta densidad (hdl) o que imita la lipoproteina de alta densidad (hdl). |
MX2021006626A MX2021006626A (es) | 2014-07-30 | 2017-01-13 | Marcadores geneticos para predecir la reactividad a terapia con agente que eleva la lipoproteina de alta densidad (hdl) o que imita la lipoproteina de alta densidad (hdl). |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2021006626A MX2021006626A (es) | 2014-07-30 | 2017-01-13 | Marcadores geneticos para predecir la reactividad a terapia con agente que eleva la lipoproteina de alta densidad (hdl) o que imita la lipoproteina de alta densidad (hdl). |
Country Status (12)
Country | Link |
---|---|
US (3) | US10584385B2 (es) |
EP (2) | EP3795695A1 (es) |
JP (2) | JP6854752B2 (es) |
KR (1) | KR102456013B1 (es) |
CN (2) | CN106559998B (es) |
CA (1) | CA2953483C (es) |
ES (1) | ES2825675T3 (es) |
IL (4) | IL300472A (es) |
MX (2) | MX2017000582A (es) |
PT (1) | PT3174995T (es) |
RU (1) | RU2703192C2 (es) |
WO (1) | WO2016016157A1 (es) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101641339B (zh) | 2007-02-01 | 2013-07-17 | 雷斯韦洛吉克斯公司 | 用于预防和治疗心血管疾病的化合物 |
MX2021012876A (es) | 2009-03-18 | 2022-06-23 | Resverlogix Corp | Nuevos agentes anti-inflamatorios. |
PT2978859T (pt) | 2013-03-27 | 2018-10-04 | Hoffmann La Roche | Marcadores genéticos para previsão da capacidade de resposta à terapêutica |
MX2017000582A (es) | 2014-07-30 | 2017-04-27 | Hoffmann La Roche | Marcadores geneticos para predecir la reactividad a terapia con agente que eleva la lipoproteina de alta densidad (hdl) o que imita la lipoproteina de alta densidad (hdl). |
US10111885B2 (en) | 2015-03-13 | 2018-10-30 | Resverlogix Corp. | Compositions and therapeutic methods for the treatment of complement-associated diseases |
US20190070178A1 (en) | 2017-08-29 | 2019-03-07 | Dalcor Pharma Uk Ltd., Stockport Zug Branch | Methods for treating or preventing cardiovascular disorders and lowering risk of cardiovascular events |
EP3696282A1 (en) * | 2019-02-14 | 2020-08-19 | Universidad del Pais Vasco | Method for diagnosing unstable atherosclerotic plaque |
BR112021014677A2 (pt) | 2019-03-07 | 2021-09-28 | Dalcor Pharma Uk Ltd., Leatherhead, Zug Branch | Métodos para tratar ou prevenir a insuficiência cardíaca e reduzir o risco de insuficiência cardíaca |
JPWO2022264678A1 (es) | 2021-06-16 | 2022-12-22 | ||
CN117587115A (zh) * | 2021-08-25 | 2024-02-23 | 华中科技大学同济医学院附属协和医院 | Il9基因中与血脂相关的snp位点及其应用 |
Family Cites Families (83)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8311018D0 (en) | 1983-04-22 | 1983-05-25 | Amersham Int Plc | Detecting mutations in dna |
US4998617A (en) | 1986-09-15 | 1991-03-12 | Laura Lupton Inc | Facial cosmetic liquid make up kit |
US6270961B1 (en) | 1987-04-01 | 2001-08-07 | Hyseq, Inc. | Methods and apparatus for DNA sequencing and DNA identification |
US5202231A (en) | 1987-04-01 | 1993-04-13 | Drmanac Radoje T | Method of sequencing of genomes by hybridization of oligonucleotide probes |
US5176996A (en) | 1988-12-20 | 1993-01-05 | Baylor College Of Medicine | Method for making synthetic oligonucleotides which bind specifically to target sites on duplex DNA molecules, by forming a colinear triplex, the synthetic oligonucleotides and methods of use |
US5256775A (en) | 1989-06-05 | 1993-10-26 | Gilead Sciences, Inc. | Exonuclease-resistant oligonucleotides |
FR2650840B1 (fr) | 1989-08-11 | 1991-11-29 | Bertin & Cie | Procede rapide de detection et/ou d'identification d'une seule base sur une sequence d'acide nucleique, et ses applications |
US5264564A (en) | 1989-10-24 | 1993-11-23 | Gilead Sciences | Oligonucleotide analogs with novel linkages |
US5210015A (en) | 1990-08-06 | 1993-05-11 | Hoffman-La Roche Inc. | Homogeneous assay system using the nuclease activity of a nucleic acid polymerase |
US6004744A (en) | 1991-03-05 | 1999-12-21 | Molecular Tool, Inc. | Method for determining nucleotide identity through extension of immobilized primer |
US5858659A (en) | 1995-11-29 | 1999-01-12 | Affymetrix, Inc. | Polymorphism detection |
US5952172A (en) | 1993-12-10 | 1999-09-14 | California Institute Of Technology | Nucleic acid mediated electron transfer |
US5968740A (en) | 1995-07-24 | 1999-10-19 | Affymetrix, Inc. | Method of Identifying a Base in a Nucleic Acid |
JP2000508912A (ja) | 1996-04-19 | 2000-07-18 | スペクトラ バイオメディカル,インコーポレイテッド | 多型形態と複数の表現型との相関付け |
JP2894445B2 (ja) | 1997-02-12 | 1999-05-24 | 日本たばこ産業株式会社 | Cetp活性阻害剤として有効な化合物 |
WO1999013108A1 (en) | 1997-09-10 | 1999-03-18 | University Of Maryland, Baltimore | Method of amplifying dna and rna mismatch cleavage products |
US6197786B1 (en) | 1998-09-17 | 2001-03-06 | Pfizer Inc | 4-Carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines |
ATE303718T1 (de) | 1999-06-04 | 2005-09-15 | Consejo Superior Investigacion | Verwendung von ölsäurereichen und stearinsäurereichen ölen |
US20030092647A1 (en) | 2001-08-08 | 2003-05-15 | Crooke Rosanne M. | Antisense modulation of cholesteryl ester transfer protein expression |
CO5271716A1 (es) | 1999-11-30 | 2003-04-30 | Pfizer Prod Inc | Cristales de 4- carboxamino 1,2,3,4-tetrahidroquinolina 2- sustituida |
AU2002323270A1 (en) | 2001-08-18 | 2003-03-03 | Myriad Genetics, Inc | Composition and method for treating hiv infection |
US20040180370A1 (en) | 2003-01-27 | 2004-09-16 | The Regents Of The University Of Colorado, A Body Corporate | Genetic diagnosis of alcoholism subtypes |
JP2006520810A (ja) | 2003-03-17 | 2006-09-14 | 日本たばこ産業株式会社 | S−[2−([[1−(2−エチルブチル)シクロヘキシル]カルボニル]アミノ)フェニル]2−メチルプロパンチオエートの経口吸収性を増加させる方法 |
TWI494102B (zh) | 2003-05-02 | 2015-08-01 | Japan Tobacco Inc | 包含s-〔2(〔〔1-(2-乙基丁基)環己基〕羰基〕胺基)苯基〕2-甲基丙烷硫酯及hmg輔酶a還原酶抑制劑之組合 |
US7276608B2 (en) | 2003-07-11 | 2007-10-02 | Bristol-Myers Squibb Company | Tetrahydroquinoline derivatives as cannabinoid receptor modulators |
US7326706B2 (en) | 2003-08-15 | 2008-02-05 | Bristol-Myers Squibb Company | Pyrazine modulators of cannabinoid receptors |
MXPA06003357A (es) | 2003-09-26 | 2006-06-08 | Japan Tobacco Inc | Metodo para inhibir la produccion de lipoproteina remanente. |
US7517900B2 (en) | 2003-10-10 | 2009-04-14 | Bristol-Myers Squibb Company | Pyrazole derivatives as cannabinoid receptor modulators |
US7420059B2 (en) | 2003-11-20 | 2008-09-02 | Bristol-Myers Squibb Company | HMG-CoA reductase inhibitors and method |
ES2284081T3 (es) | 2003-12-19 | 2007-11-01 | Bristol-Myers Squibb Company | Heterociclos azabiciclicos como modulares de receptores canabinoides. |
JP2007514768A (ja) | 2003-12-19 | 2007-06-07 | ブリストル−マイヤーズ スクイブ カンパニー | カンナビノイド受容体調整物質としてのアザ二環式複素環 |
EP1735055A1 (en) | 2004-03-30 | 2006-12-27 | Sapphire Therapeutics, Inc. | Method of reducing c-reactive protein using growth hormone secretagogues |
DOP2005000123A (es) | 2004-07-02 | 2011-07-15 | Merck Sharp & Dohme | Inhibidores de cetp |
ES2384980T3 (es) | 2004-12-18 | 2012-07-16 | Bayer Pharma Aktiengesellschaft | Derivados de tetrahidroquinolina sustituidos en 4 con cicloalquilo y su uso como medicamentos |
EP1841436A4 (en) | 2005-01-05 | 2008-02-20 | Medicure Int Inc | COMPOUNDS AND METHOD FOR REGULATING TRIGLYCERID MIRRORS |
WO2006099142A2 (en) * | 2005-03-10 | 2006-09-21 | The Trustees Of Boston University | Prognostic method for vascular diseases |
JP2006288279A (ja) | 2005-04-11 | 2006-10-26 | Otsuka Pharmaceut Co Ltd | 出血時間延長傾向判定方法 |
US7863307B2 (en) | 2005-07-01 | 2011-01-04 | Merck Sharp & Dohme | Process for synthesizing a CETP inhibitor |
BRPI0617621A2 (pt) | 2005-10-21 | 2011-08-02 | Novartis Ag | combinação de compostos orgánicos |
US7435849B2 (en) | 2005-10-31 | 2008-10-14 | Hoffmann-La Roche Inc. | Process for the production of acid chlorides |
AU2006313430B2 (en) | 2005-11-08 | 2012-09-06 | Ranbaxy Laboratories Limited | Process for (3R,5R)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4- [(4-hydroxy methyl phenyl amino) carbonyl]-pyrrol-1-yl]-3, 5-dihydroxy-heptanoic acid hemi calcium salt |
WO2007071824A1 (en) * | 2005-12-20 | 2007-06-28 | Oy Jurilab Ltd | Novel genes and markers associated with high-density lipoprotein -cholesterol (hdl-c) |
PE20080251A1 (es) | 2006-05-04 | 2008-04-25 | Boehringer Ingelheim Int | Usos de inhibidores de dpp iv |
US20090035306A1 (en) | 2006-11-29 | 2009-02-05 | Kalypsys, Inc. | Quinazolinone modulators of tgr5 |
EP1935867A1 (en) | 2006-12-20 | 2008-06-25 | F. Hoffmann-La Roche Ag | Process for preparing 1-(2-ethyl-butyl)-cyclohexanecarboxylic acid |
US20080221161A1 (en) | 2007-02-09 | 2008-09-11 | Kalypsys, Inc. | Heterocyclic modulators of tgr5 for treatment of disease |
EP2150520B1 (en) | 2007-04-25 | 2012-10-31 | F. Hoffmann-La Roche AG | Novel process for the preparation of acid chlorides |
US20090054304A1 (en) | 2007-08-23 | 2009-02-26 | Kalypsys, Inc. | Heterocyclic modulators of tgr5 for treatment of disease |
WO2009026241A1 (en) | 2007-08-23 | 2009-02-26 | Kalypsys, Inc. | Heterocyclic modulators of tgr5 |
KR101290935B1 (ko) | 2008-04-04 | 2013-07-29 | 에프. 호프만-라 로슈 아게 | 상응하는 사이클로헥세인카복스아마이드 유도체에 의한 사이클로헥세인카복실산 유도체의 신규한 제조 방법 |
BRPI0909813B1 (pt) | 2008-04-04 | 2018-01-02 | F. Hoffmann-La Roche Ag | "processos para preparação de derivados de ácido ciclo-hexanocarboxílico, e intermediário" |
CN102066311B (zh) | 2008-06-17 | 2014-07-02 | 弗·哈夫曼-拉罗切有限公司 | 用作药物活性酰胺制备中的中间体的1-(2-乙基丁基)-环己烷羧酸酯 |
EP2177615A1 (en) | 2008-10-10 | 2010-04-21 | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. | Method for a genome wide identification of expression regulatory sequences and use of genes and molecules derived thereof for the diagnosis and therapy of metabolic and/or tumorous diseases |
US20100183598A1 (en) | 2008-11-12 | 2010-07-22 | Carolus Therapeutics, Inc. | Methods of treating cardiovascular disorders |
WO2010066593A1 (en) | 2008-12-08 | 2010-06-17 | F. Hoffmann-La Roche Ag | Combined drug administration |
US20120021982A1 (en) * | 2009-01-23 | 2012-01-26 | Jean-Claude Tardif | Pharmaceutical compositions for the treatment of left ventricular diastolic dysfunction |
NZ624963A (en) | 2009-04-29 | 2016-07-29 | Amarin Pharmaceuticals Ie Ltd | Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same |
TWI450896B (zh) | 2009-06-30 | 2014-09-01 | Lilly Co Eli | 反式-4-〔〔(5s)-5-〔〔〔3,5-雙(三氟甲基)苯基〕甲基〕(2-甲基-2h-四唑-5-基)胺基〕-2,3,4,5-四氫-7,9-二甲基-1h-1-苯并氮呯-1-基〕甲基〕-環己基羧酸 |
US20110004011A1 (en) | 2009-07-01 | 2011-01-06 | Declan Costello | Novel process |
EP2454271A4 (en) | 2009-07-15 | 2015-08-12 | Univ California | PEPTIDES WITH CONTROLLABLE CELLULAR RECORDING |
CA2795750A1 (en) * | 2010-04-07 | 2011-10-13 | Isis Pharmaceuticals, Inc. | Modulation of cetp expression |
CA2809215A1 (en) | 2010-09-16 | 2012-03-22 | F. Hoffmann-La Roche Ag | New process |
WO2012059447A1 (en) | 2010-11-04 | 2012-05-10 | F. Hoffmann-La Roche Ag | A composition comprising s-[2-([[1-(2-ethylbutyl)-cyclohexyl]-carbonyl]amino)phenyl]2-methylpropanethioate and croscarmellose sodium |
WO2012069087A1 (en) | 2010-11-25 | 2012-05-31 | Mediasuccess Gmbh | Automatic text generation |
CA2818018C (en) * | 2010-12-08 | 2016-02-02 | F. Hoffmann-La Roche Ag | Liposomal formulation of dalcetrapib |
ES2705496T3 (es) | 2010-12-16 | 2019-03-25 | Hoffmann La Roche | Procedimiento para la preparación de derivados de tiol aromáticos por hidrogenación de disulfuros |
US20140044668A1 (en) * | 2011-02-15 | 2014-02-13 | The Ohio State University | Methods for Predicting Cardiovascular Risks and Responsiveness to Statin Therapy Using SNPs |
CN103391769A (zh) * | 2011-02-17 | 2013-11-13 | 霍夫曼-拉罗奇有限公司 | 通过热熔挤出使活性药物成分从过冷液体状态受控结晶的方法 |
US9541565B2 (en) | 2011-04-08 | 2017-01-10 | Zora Biosciences Oy | Biomarkers for sensitive detection of statin-induced muscle toxicity |
CA2868372A1 (en) | 2011-04-08 | 2012-10-11 | Zora Biosciences Oy | Biomarkers for sensitive detection of statin-induced muscle toxicity |
EP2702400A4 (en) * | 2011-04-29 | 2015-06-17 | Childrens Hosp & Res Ct Oak | COMPOSITIONS AND METHODS FOR ASSESSING THE CAPACITY OF HDL IN SUPPORT OF CHOLESTER REVERSE TRANSPORT |
US20120301439A1 (en) | 2011-05-24 | 2012-11-29 | Washington University | Inhibition of choroidal neovascularization |
US8975438B2 (en) | 2011-07-13 | 2015-03-10 | Hoffmann-La Roche Inc. | Process for the preparation of cyclohexanecarboxylic acid derivatives |
AR089853A1 (es) | 2012-02-01 | 2014-09-24 | Boehringer Ingelheim Int | Inhibidores de oxadiazol de la produccion de leucotrienos para terapia de combinacion, composicion farmaceutica, uso |
EA201400976A1 (ru) | 2012-03-06 | 2015-02-27 | Бёрингер Ингельхайм Интернациональ Гмбх | Бензодиоксаны в комбинации с другими активными средствами для ингибирования продуцирования лейкотриена |
CN104244946A (zh) | 2012-04-30 | 2014-12-24 | 霍夫曼-拉罗奇有限公司 | 新制剂 |
MX351059B (es) | 2012-08-17 | 2017-09-29 | Laboratorios Senosiain S A De C V Star | Composicion farmaceutica oral en forma de microesferas y proceso de elaboracion. |
PT2978859T (pt) | 2013-03-27 | 2018-10-04 | Hoffmann La Roche | Marcadores genéticos para previsão da capacidade de resposta à terapêutica |
JP6539661B2 (ja) | 2013-12-19 | 2019-07-03 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | 眼疾患の処置において使用するためのcetpモデュレーター |
GB201401617D0 (en) * | 2014-01-30 | 2014-03-19 | Helperby Therapeutics Ltd | Novel combination and use |
MX2017000582A (es) | 2014-07-30 | 2017-04-27 | Hoffmann La Roche | Marcadores geneticos para predecir la reactividad a terapia con agente que eleva la lipoproteina de alta densidad (hdl) o que imita la lipoproteina de alta densidad (hdl). |
US20190070178A1 (en) | 2017-08-29 | 2019-03-07 | Dalcor Pharma Uk Ltd., Stockport Zug Branch | Methods for treating or preventing cardiovascular disorders and lowering risk of cardiovascular events |
CN112888432A (zh) | 2018-08-09 | 2021-06-01 | 英国达科(莱得海德)制药有限公司-楚歌分公司 | 用于延迟新发作2型糖尿病的发生和用于减慢2型糖尿病的进展和治疗2型糖尿病的方法 |
-
2015
- 2015-07-27 MX MX2017000582A patent/MX2017000582A/es unknown
- 2015-07-27 EP EP20184540.1A patent/EP3795695A1/en not_active Withdrawn
- 2015-07-27 ES ES15742250T patent/ES2825675T3/es active Active
- 2015-07-27 WO PCT/EP2015/067098 patent/WO2016016157A1/en active Application Filing
- 2015-07-27 CN CN201580040416.9A patent/CN106559998B/zh active Active
- 2015-07-27 CN CN202210024117.8A patent/CN114381512A/zh active Pending
- 2015-07-27 RU RU2017104149A patent/RU2703192C2/ru active
- 2015-07-27 IL IL300472A patent/IL300472A/en unknown
- 2015-07-27 PT PT157422502T patent/PT3174995T/pt unknown
- 2015-07-27 EP EP15742250.2A patent/EP3174995B1/en active Active
- 2015-07-27 CA CA2953483A patent/CA2953483C/en active Active
- 2015-07-27 KR KR1020177002272A patent/KR102456013B1/ko active IP Right Grant
- 2015-07-27 JP JP2017504647A patent/JP6854752B2/ja active Active
-
2017
- 2017-01-13 MX MX2021006626A patent/MX2021006626A/es unknown
- 2017-01-25 US US15/415,112 patent/US10584385B2/en active Active
- 2017-01-26 IL IL250308A patent/IL250308B/en active IP Right Grant
-
2020
- 2020-01-27 US US16/773,040 patent/US11401554B2/en active Active
-
2021
- 2021-03-16 JP JP2021042828A patent/JP7244560B2/ja active Active
- 2021-03-30 IL IL281905A patent/IL281905B/en unknown
-
2022
- 2022-01-25 IL IL290115A patent/IL290115B2/en unknown
- 2022-06-16 US US17/842,282 patent/US20230151424A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2021006626A (es) | Marcadores geneticos para predecir la reactividad a terapia con agente que eleva la lipoproteina de alta densidad (hdl) o que imita la lipoproteina de alta densidad (hdl). | |
IL249370A0 (en) | Fap-enabled medical substances and related uses | |
MX2020005213A (es) | Inhibidores de proteina cinasa 2 activada por proteina cinasa activada por mitogeno (mk2) y sus usos. | |
PH12017500621A1 (en) | Triazolopyrazinones as pde1 inhibitors | |
ZA201702799B (en) | 2-amino-3,5-difluoro-3,6-dimethyl-6-phenyl-3,4,5,6-tetrahydropyridines as bace1 inhibitors for treating alzheimer's disease | |
PH12016502167A1 (en) | Hdl theraphy markers | |
SG10201808940WA (en) | Nox inhibitor and nfкb inhibitor containing methoxyflavone | |
HK1247216A1 (zh) | 微生物轉谷氨酰胺酶,其底物和其使用方法 | |
MY176855A (en) | Anti-jagged1 antibodies and methods of use | |
MX2017004448A (es) | Compuestos anti-factor de necrosis tumoral (tnf). | |
MX2019015058A (es) | Marcadores geneticos para la prediccion de respuesta a la terapia. | |
MX2017004927A (es) | Metodos de evaluacion genomica en ganado. | |
MX2018011875A (es) | Reprogramacion cardiaca directa mejorada. | |
MX2022001801A (es) | Secuencias recombinantes de cromosoma b de maiz y sus usos. | |
PH12017501022B1 (en) | Compositions comprising 15-hepe and methods of treating or preventing fibrosis using same | |
IL250844A0 (en) | Medical nanoparticles and related preparations, methods and systems | |
PH12016501495A1 (en) | Hexahydrofuropyrroles as pde1 inhibitors | |
MX2016009665A (es) | Composiciones y metodos para el tratamiento de la hemorragia cerebral. | |
GB201417148D0 (en) | Eukaryotic expression vector encoding canine interleukin 12 for cancer gene therapy and the use thereof | |
NZ764110A (en) | Compositions and methods for modulating pkk expression | |
PH12014000104A1 (en) | Therapeutic methods and compositions for treating diabetes | |
AU354883S (en) | Plastic bar chair for reinforcing steel | |
AU354768S (en) | Plastic bar chair for chairing reinforcing steel | |
AU354764S (en) | Plastic bar chair for chairing reinforcing steel |